Targeted Oncology2h
FDA Considers Approval of TLX250-CDx in Kidney Cancer
A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...
Targeted Oncology3h
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
Targeted Oncology1h
Recent Updates from SKIPPirr – Strategies for Preventing IRR with IV Amivantamab in Patients with EGFR-mutated NSCLC
A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.
Targeted Oncology6h
Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection
Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient ...
Targeted Oncology6h
Newly Diagnosed mHSPC: First-Line Treatment Options
Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or ...